Shares of Allurion (NYSE:ALUR) soared 70% in post-market trading Thursday after ending the regular session 21% higher on news the company plans to conduct a clinical study of its gastric balloon ...

550 subjects were randomized 1:1 to either two cycles of the Allurion Balloon 1 or a control group that received moderate intensity lifestyle therapy. Subjects in the treatment group received ...

At 48 weeks, Allurion Balloon subjects had a greater than 50% responder rate and substantially greater weight loss than Control subjects Low rate of serious adverse events supports favorable ...

Allurion Technologies announced it would begin a study to see if its gastric balloon, combined with popular GLP-1 medicines like Novo Nordisk's Wegovy, could improve muscle mass and overall body ...

The Company plans to submit the fourth and final module of the Pre-Market Approval application to the FDA. Topline data were announced from the AUDACITY trial evaluating the Allurion Gastric ...

Allurion Technologies (ALUR) announced topline results from the AUDACITY FDA pivotal trial evaluating the safety and efficacy of the Allurion Balloon. The AUDACITY trial is an open-label ...

A HOLOCAUST survivor has revealed she was minutes away from being sent to her death at Auschwitz - before her train was diverted in a lucky twist of fate. Agnes Kaposi, 92, was just 11 years old ...

Returning to work after a stroke is a significant concern for many survivors, especially those of working age. Stroke can lead to various physical and cognitive impairments, which can hinder an ...

1 In contrast, in previous studies, patients treated with the Allurion Balloon in combination with the Allurion Virtual Care Suite have demonstrated strong patient outcomes in which patients lose ...

Allurion (NYSE: ALUR) surged 83% premarket after revealing a clinical study combining its gastric balloon product with GLP-1 drugs, showing muscle mass maintenance. Stardust Power (NASDAQ ...